Retinitis pigmentosa – treatment modalities – review

Kamila Krasodomska, Wojciech Lubiński


Introduction: Progressive nature and lack of effective treatment of the retinitis pigmentosa (RP) leads to search for the new therapeutic methods to stop progression of the disease.

The aim of this study is to review the current treatment modalities that may influence progression of RP.

Materials and methods: Based on the results reported in the available literature, non-pharmacological and pharmacological investigation in RP has been reviewed.

Results: The results of numerous studies indicate that so far there is no cure for RP. However, there are methods that can slow down progression of the disease.

Conclusions: Therapeutic treatment of patients with RP should be focused on providing psychological care, education planning, assistance in making a decision about a future profession or having children. Ophthalmologists should provide partially sighted people with a complete list of available optical systems, as well as treat cataract and cysts macular changes often associated with RP.


retinitis pigmentosa; pharmacological treatment; non-pharmacological treatment

Full Text:

PDF (Język Polski)


Haim M. Epidemiology of retinitis pigmentosa in Denmark. Acta Ophthalmol Scand Suppl 2002;233:1-34.

Chang S, Vaccarella L, Olatunji S, Cebulla C, Christoforidis J. Diagnostic challenges in retinitis pigmentosa: genotypic multiplicity and phenotypic variability. Curr Genomics 2011;12(4):267-75. doi:10.2174/138920211795860116.

Rayapudi S, Schwartz SG, Wang X, Chavis P. Vitamin A and fish oils for retinitis pigmentosa. Cochrane Database Syst Rev 2013;12:CD008428. doi: 10.1002/14651858.CD008428.pub2.

Hamel C. Retinitis pigmentosa. Orphanet J Rare Dis 2006;1:40. doi: 10.1186/1750-1172-1-40.

Fishman GA, Apushkin MA. Continued use of dorzolamide for the treatment of cystoid macular oedema in patients with retinitis pigmentosa. Br J Ophthalmol 2007;91(6):743-5. doi: 10.1136/bjo.2006.107466.

Sacchetti M, Mantelli F, Lambiase A, Mastropasqua A, Merlo D, Bonini S. Systematic review of randomised clinical trials on topical ciclosporin A for the treatment of dry eye disease. Br J Ophthalmol 2014;98(8):1016-22. doi: 10.1136/bjophthalmol-2013-304072.

Wang M, Lam TT, Tso MO, Naash MI. Expression of a mutant opsin gene increases the susceptibility of the retina to light damage. Vis Neurosci 1997;14(1):55-62.

Vingolo EM, Rocco M, Grenga P, Salvatore S, Pelaia P. Slowing the degenerative process, long lasting effect of hyperbaric oxygen therapy in retinitis pigmentosa. Graefes Arch Clin Exp Ophthalmol 2008;246(1):93-8. doi: 10.1007/s00417-007-0652-z.

Berson EL, Rosner B, Sandberg MA, Hayes KC,Nicholson BW, Weigel--DiFranco C, et al. A randomized trial of vitamin A and vitamin E supplementation for retinitis pigmentosa. Arch Ophthalmol 1993;111(6):761-72.

Berson EL, Rosner B, Sandberg MA, Weigel-DiFranco C, Moser A, Brockhurst RJ, et al. Clinical trial of docosahexaenoic acid in patients with retinitis pigmentosa receiving vitamin A treatment. Arch Ophthalmol 2004;122(9):1297-305. doi: 10.1001/archopht.122.9.1297.

Berson EL, Rosner B, Sandberg MA, Weigel-DiFranco C, Moser A, Brockhurst RJ, et al. Further evaluation of docosahexaenoic acid in patients with retinitis pigmentosa receiving vitamin A treatment: subgroup analyses. Arch Ophthalmol 2004;122(9):1306-14. doi: 10.1001/archopht. 122.9.1306.

Hoffman DR, Locke KG, Wheaton DH, Fish GE, Spencer R, Birch DG. A randomized, placebo-controlled clinical trial of docosahexaenoic acid supplementation for X-linked retinitis pigmentosa. Am J Ophthalmol 2004;137(4):704-18. doi: 10.1016/j.ajo.2003.10.045.

Bahrami H, Melia M, Dagnelie G. Lutein supplementation in retinitis pigmentosa: PC-based vision assessment in a randomized double-masked placebo-controlled clinical trial [NCT00029289]. BMC Ophthalmol 2006;6:23. doi: 10.1186/1471-2415-6-23.

Berson EL, Rosner B, Sandberg MA, Weigel-DiFranco C, Brockhurst RJ, Hayes KC, et al. Clinical trial of lutein in patients with retinitis pigmentosa receiving vitamin A. Arch Ophthalmol 2010;128(4):403-11. doi: 10.1001/archophthalmol.2010.32.

Kumar A, Midha N, Gogia V, Gupta S, Sehra S, Choha A. Efficacy of oral valproic acid in patients with retinitis pigmentosa. J Ocul Pharmacol Ther 2014;30(7):580-6. doi: 10.1089/jop.2013.0166.

Iraha S, Hirami Y, Ota S, Sunagawa GA, Mandai M, Tanihara H. Efficacy of valproic acid for retinitis pigmentosa patients: a pilot study. Clin Ophthalmol 2016;10:1375-84. doi: 10.2147/OPTH.S109995.

Rotenstreich Y, Belkin M, Sadetzki S, Chetrit A, Ferman-Attar G, Sher I, et al. Treatment with 9-cis β v

Merin S, Obolensky A, Farber MD, Chowers I. A pilot study of topical treatment with an alpha2-agonist in patients with retinal dystrophies. J Ocul Pharmacol Ther 2008;24(1):80-6. doi: 10.1089/jop.2007.0022.

Birch DG, Weleber RG, Duncan JL, Jaffe GJ, Tao W. Randomized trial of ciliary neurotrophic factor delivered by encapsulated cell intraocular implants for retinitis pigmentosa. Am J Ophthalmol 2013;156(2):283-92. doi: 10.1016/j.ajo.2013.03.021.

Nakazawa M, Ohguro H, Takeuchi K, Miyagawa Y, Ito T, Metoki T. Effect of nilvadipine on central visual field in retinitis pigmentosa: a 30-month clinical trial. Ophthalmologica 2011;225(2):120-6. doi: 10.1159/000320500.

Lin MK, Tsai YT, Tsang SH. Emerging treatments for retinitis pigmentosa: Genes and stem cells, as well as new electronic and medical therapies, are gaining ground. Retin Physician 2015;12:52-70.

Bainbridge JW, Mehat MS, Sundaram V, Robbie SJ, Barker SE, Ripamonti C, et al. Long-term effect of gene therapy on Leber’s congenital amaurosis. N Engl J Med 2015;372(20):1887-97. doi: 10.1056/NEJMoa1414221.

Sengillo JD, Justus S, Tsai YT, Cabral T, Tsang SH. Gene and cell-based therapies for inherited retinal disorders: An update. Am J Med Genet C Semin Med Genet 2016;172(4):349-366. doi: 10.1002/ajmg.c.31534.

He Y, Zhang Y, Liu X, Ghazaryan E, Li Y, Xie J, et al. Recent advances of stem cell therapy for retinitis pigmentosa. Int J Mol Sci 2014;15(8):14456-74. doi: 10.3390/ijms150814456.

Siqueira RC, Messias A, Voltarelli JC, Scott IU, Jorge R. Intravitreal injection of autologous bone marrow-derived mononuclear cells for hereditary retinal dystrophy: a mononuclear cells for hereditary retinal dystrophy: a phase I trial. Retina 2011;31(6):1207-14. doi: 10.1097/IAE.0b013e3181f9c242.

Siqueira RC, Messias A, Messias K, Arcieri RS, Ruiz MA, Souza NF, et al. Quality of life in patients with retinitis pigmentosa submitted to intravitreal use of bone marrow-derived stem cells (Reticell-clinical trial). Stem Cell Res Ther 2015;6:29. doi: 10.1186/s13287-015-0020-6.

Berson EL. Nutrition and retinal degenerations: Vitamin A, taurine, ornithine, and phytanic acid. Retina 1982;2(4):236-55.

Chen Y, Houghton LA, Brenna JT, Noy N. Docosahexaenoic acid modulates the interactions of the interphotoreceptor retinoid-binding protein with 11-cis retinal. J Biol Chem 1996;271(34):20507-15.

Sommerburg OG, Siems WG, Hurst JS, Lewis JW, Kliger DS, van Kuijk FJ. Lutein and zeaxanthin are associated with photoreceptors in the human retina. Curr Eye Res1999;19(6):491-5.

Kubota A, Nishida K, Nakashima K, Tano Y. Conversion of mammalian Müller glial cells into a neuronal lineage by in vitro aggregate-culture. Biochem Biophys Res Commun 2006;351(2):514-20. doi: 10.1016/j.bbrc.2006.10.072.

Göttlicher M, Minucci S, Zhu P, Krämer OH, Schimpf A, Giavara S. Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J 2001;20(24):6969-78. doi: 10.1093/emboj/20.24.6969.

Bhalla S, Joshi D, Bhullar S, Kasuga D, Park Y, Kay CN. Long-term follow-up for efficacy and safety of treatment of retinitis pigmentosa with valproic acid. J Ophthalmol 2013;97(7):895-9. doi: 10.1136/bjophthalmol-2013-303084.

Ben-Amotz A, Lers A, Avron M. Stereoisomers of beta-carotene and phytoene in the Alga Dunaliella bardawil. Plant Physiol 1988;86(4):1286-91.

Wen R, Tao W, Li Y, Sieving PA. CNTF and retina. Prog Retin Eye Res 2012;31(2):136-51. doi: 10.1016/j.preteyeres.2011.11.005.

Portera-Cailliau C, Sung CH, Nathans J, Adler R. Apoptotic photoreceptor cell death in mouse models of retinitis pigmentosa. Proc Natl Acad Sci U S A 1994;91(3):974-8.

Nicotera P, Orrenius S. The role of calcium in apoptosis. Cell Calcium 1998;23(2-3):173-80.

Maguire AM, Simonelli F, Pierce EA, Pugh EN Jr, Mingozzi F, Bennicelli J, et al. Safety and efficacy of gene transfer for Leber’s congenital amaurosis. N Engl J Med 2008;358(21):2240-8. doi: 10.1056/NEJMoa0802315.

Ghazi NG, Abboud EB, Nowilaty SR, Alkuraya H, Alhommadi A, Cai H, et al. Treatment of retinitis pigmentosa due to MERTK mutations by ocular subretinal injection of adeno-associated virus gene vector: results of a phase I trial. Hum Genet 2016;135(3):327-43. doi: 10.1007/s00439-016-1637-y.

Kicic A, Shen WY, Wilson AS, Constable IJ, Robertson T, Rakoczy PE. Differentiation of marrow stromal cells into photoreceptors in the rat eye. J Neurosci 2003;23(21):7742 9.

Jin ZB, Okamoto S, Xiang P, Takahashi M. Integration free induced pluripotent stem cells derived from retinitis pigmentosa patient for disease modeling. Stem Cell Trans Med 2012;1(6):503-9. doi: 10.5966/sctm.2012-0005.

Tucker BA, Mullins RF, Streb LM, Anfinson K, Eyestone ME, Kaalberg E, et al. Patient-specific iPSC-derived photoreceptor precursor cells as a means to investigate retinitis pigmentosa. Elife 2013;2:e00824. doi:10.7554/eLife.00824.


Copyright (c) 2017 Kamila Krasodomska, Wojciech Lubiński

License URL: